EMA Confirms Acceptance of Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab) : vimarsana.com

Partners Alvotech and STADA have marketing authorization application (MAA) for ustekinumab accepted for filing by the European Medicines Agency (EMA)

Related Keywords

Bad Vilbel , Hessen , Germany , Yangtze River , China General , China , Malaysia , Taiwan , Japan , Philippines , United States , Hong Kong , Vietnam , Republic Of , Indonesia , Pakistan , Bangladesh , India , Thailand , New Zealand , Israel , Singapore , Cambodia , Reykjavik , C10 , Iceland , South Korea , Bryan Kim , Africa , Saval Latin America , Joseph Mcclellan , Robert Wessman , Kamada Ltd , Lotus Pharmaceuticals Co Ltd , Pharma Corporation Canada , Teva Pharmaceuticals , Teva Pharmaceutical Industries Ltd , Fuji Pharma Co Ltd Japan , European Medicines Agency , Yangtze River Pharmaceutical Group Co Ltd , Johnson , Partners Alvotech , Proposed Biosimilar , Marketing Authorization Application , Chief Scientific Officer , South America , Teva Pharmaceutical Industries , Cipla Med Pro , Yangtze River Pharmaceutical , Middle East , North Africa , Abdi Ibrahim , Mega Labs , Latin America , Stada , Alvotech , Biosimilar ,